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The propensity of LDLs (low-density lipoproteins) for aggregation and/or oxidation has been linked to their sphingolipid
content, specifically the levels of SM (sphingomyelin) and ceramide. To investigate this association in vivo, ldlr (LDL
receptor)-null mice (ldlr − / − ) were fed on a modified (atherogenic) diet containing saturated fats and cholesterol. The
diet led to significantly elevated SM content in all serum lipoproteins. In contrast, ceramide increased only in the LDL
particles. MS-based analyses of the lipid acyl chain composition revealed a marked elevation in C16:0 fatty acid in SM
and ceramide, consistent with the prevalence of palmitic acid in the modified diet. The diet also led to increased activity
of the S-SMase [secretory SMase (sphingomyelinase)], a protein that is generated by ASMase (acid SMase) and acts
on serum LDL. An increased macrophage secretion seemed to be responsible for the elevated S-SMase activity.
ASMase-deficient mice (asm − / − /ldlr − / − ) lacked S-SMase activity and were protected from diet-induced elevation
in LDL ceramide. LDL from asm − / − /ldlr − / − mice fed on the modified diet were less aggregated and oxidized than
LDL from asm + / + /ldlr − / − mice. When tested in vitro, the propensity for aggregation was dependent on the SM
level: only LDL from animals on modified diet that have high SM content aggregated when treated with recombinant
S-SMase. In conclusion, LDL-SM content and S-SMase activity are up-regulated in mice fed on an atherogenic diet.
S-SMase mediates diet-induced changes in LDL ceramide content and aggregation. S-SMase effectiveness in inducing
aggregation is dependent on diet-induced enrichment of LDL with SM, possibly through increased hepatic synthesis.
Key words: atherosclerosis, ceramide, low-density lipoprotein aggregation, sphingomyelin, secretory
sphingomyelinase
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INTRODUCTION
SM (sphingomyelin) is a major lipid component of LDL
(low-density lipoprotein) particles and together with phosphatidylcholine forms the polar surface of the lipoproteins. The
SM found in the lipoproteins originates from the liver, where it
is generated via the de novo pathway of sphingolipid synthesis
and then incorporated into VLDL (very-low-density lipoprotein)
particles for secretion in the circulation. The availability of SM

%

for lipoprotein formation depends on the rate-limiting step in its
de novo synthesis, the SPT (serine-palmitoyl transferase) reaction
[1,2]. SPT generates dihydrosphingosine, which is converted consequentially into dihydroceramide, ceramide and SM. S-SMase
[secretory SMase (sphingomyelinase)] can convert SM in atherogenic serum lipoprotein particles back into ceramide [3,4]. The
S-SMase enzyme, secreted by macrophages and endothelial cells,
is an alternatively modified form of the 75 kDa protein product
of the asm gene [encoding ASMase (acid SMase)], which also
produces the lysosomal form of ASMase [5].

.................................................................. ............................................................. ................................................................. .............................................................. ..............................................

Abbreviations used: ABV, aorta and blood vessel; apoE, apolipoprotein E; C6 -NBD-Cer, 6-[N-(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]hexanoylceramide; C6 -NBD-SM,
6-[N-(7-nitro-2,1,3-benzoxadiazol-4-yl) amino]hexanoylsphingosylphosphocholine; ESI, electrospray ionization; HDL, high-density lipoprotein; LDL, low-density lipoprotein; ldlr, LDL
receptor; L-SMase, lysosomal ASMase; SM, sphingomyelin; SMase, sphingomyelinase; ASMase, acid SMase; bSMase, bacterial SMase; SPT, serine-palmitoyl transferase; S-SMase,
secretory SMase; TBARS, thiobarbituric acid-reactive substances; VLDL, very-low-density lipoprotein
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Plasma SM levels have been shown to correlate with the incidence of diet-induced atherosclerosis in primates, inherent atherosclerosis in WHHL (Watanabe hereditable hyperlipidaemic)
rabbits and coronary heart disease in humans [6–9]. LDL particles
isolated from human arteriosclerotic lesions have high SM levels,
implying that increases in serum SM are linked to sub-endothelial
retention of atherogenic LDL particles [10]. In contrast, lowering the plasma SM content in apoE (apolipoprotein E) − / − mice
through the pharmacological inhibition of SM synthesis in liver
delays the development of atherosclerotic lesions by 42 % without
having any effect on total serum cholesterol or triacylglycerols
[9,11,12]. These studies suggest that SM in lipoproteins may influence their atherogenic properties and thus the progression of
atherosclerosis. It remains unclear, however, how the elevated
SM in the circulation increases the risks for the development of
atherosclerosis.
Several studies have shown that the rate of de novo synthesis
and incorporation of SM in serum lipoproteins, as well as its
degradation by the S-SMase is regulated [2,9,13,14]. Increased
consumption of diets enriched in saturated fats and cholesterol
leads to stimulation of de novo synthesis of sphingolipids in the
liver [13]. The main saturated fat in these diets, palmitic acid, is
a substrate for SPT and when provided in excess can stimulate
SPT mRNA expression and activity [2,13]. These changes are
paralleled by elevation in total plasma ceramide and SM content
[9]; however, the effects atherogenic diet have on sphingolipid
composition of the individual lipoproteins have not been studied. S-SMase activity, in turn, also seems to be regulated. It
increases in response to IL-1β (interleukin-1β) and IFNγ (interferon γ ) stimulation of macrophages [14], in patients with
CHF (chronic heart failure) [15] and Type 2 diabetes mellitus
[16]. Notably, activation of S-SMase may be directly linked to
the development of atherosclerosis because elevation of ceramide content in LDL particles has been shown to enhance the
activity of secretory PLA2 (phospholipase A2 ) [17], to promote
LDL uptake in macrophages and to facilitate foam cell formation
[18]. Ceramide-enriched LDL is isolated from atherosclerotic
plaques [19,20] and is associated with accelerated LDL aggregation [21] and microvascular endothelial cell apoptosis [22,23].
Indeed, in vitro treatment of human LDL particles with bSMase
(bacterial SMase), which similarly to S-SMase converts LDL-SM
into ceramide, induces LDL aggregation [24] and oxidation [25].
It has been suggested that the sub-endothelial retention of LDL is
facilitated by S-SMase-induced aggregation and binding of LDL
to the matrix proteoglycans [26,27]. In contrast, asm ablation
in vivo slows down the sub-endothelial lipoprotein retention and
the development of lesions in apoE − / − and ldlr − / − mice [28].
Despite these indications that S-SMase is critical for aggregation of LDL particles, direct evidence for regulation of S-SMase
activity during atherosclerosis and its role in LDL modification is still missing. In the present study, we used C57Bl6
and ldlr − / − mice that have ASMase deficiency (asm − / − ) to
characterize the effects an atherogenic diet has on sphingolipid
content of lipoproteins and S-SMase activity and to investigate how S-SMase affects the propensity of LDL particles for
aggregation.

EXPERIMENTAL
Materials
C6 -NBD-Cer {6-[N-(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]hexanoylceramide} and C6 -NBD-SM {6-[N-(7-nitro-2,1,3benzoxadiazol-4-yl)amino]hexanoylsphingosylphosphocholine}
were from Molecular Probes, C17:0 ceramide (N-heptadecanoyl-D-erythro-sphingosine), C17:0 SM (N-heptadecanoylD-erythro-sphingosylphosphocholine),
N-acetyl-C20 -sphinganine and bovine brain ceramide were purchased from Avanti
Polar Lipids. bSMase was from Sigma–Aldrich. Lowry total
protein determination kit (Dc protein Assay) was from Bio-Rad.
All other reagents were from Fisher Scientific.

Animals and diets
A colony of ASMase-deficient mice (asm − / − ) in C56Bl6
background was maintained in the AAALAC (Association
for Assessment and Accreditation of Laboratory Animal Care
International)-approved animal facility of University of Kentucky Medical Center by breeding heterozygous asm + / − mice.
asm − / − /ldlr − / − , a double knockout mouse colony, was generated and maintained in our laboratory as described previously by litter mating of asm + / − /ldlr − / − animals [13].
Litter-matched asm − / − /ldlr − / − and asm − / − offspring and
their respective controls – asm + / + /ldlr − / − and asm + / + were
used throughout the experiments. After weaning, all mice
were genotyped [29] and placed on a standard chow diet (2918,
Teklad-Global; 18 % protein rodent diet; Harlan-Teklad), 12 h
light/12 h dark cycle in micro-isolation. Eight-week-old littermatched mice from both genders were randomly placed on
either a diet rich in saturated fats and cholesterol (modified diet,
TD.88137, adjusted calorie diet, 42 % from fat) (Harlan-Teklad)
or continued on the standard diet for a period of 10 weeks. At
the end of the diet, mice were deeply anaesthetized, blood was
collected by heart puncture and the serum was obtained in serum
separator tubes. Liver was dissected, flash-frozen in liquid nitrogen and kept at − 80 ◦ C until further processed. All animal experimentations were included in our animal protocol, approved
by IACUC (Institutional Animal Care and Use Committee) and
carried out in complete agreement with the recommendations of
the AVMA (American Veterinary Medical Association).

Isolation of lipoprotein fractions
Lipoproteins were separated by sequential ultracentrifugation
in Beckman Optima tabletop ultracentrifuge (Beckman Instruments) following a previously described procedure [30] with
some modifications. Briefly, fresh serum was centrifuged at
540 000 g at 4 ◦ C for 3.7 h at a density of 1.019 g/ml to obtain
VLDL (very-LDL), for 3.4 h at 1.063 g/ml for LDL and for 6.8 h
at a density of 1.21 g/ml for HDL (high-density lipoproteins).
After isolation, lipoprotein particles were dialysed overnight at
4 ◦ C against PBS using 0.5–3 ml Dialysis Cassettes (Pierce).
The VLDL, LDL and HDL were stored under argon to prevent
oxidation. Quality and physical properties of freshly isolated
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lipoprotein fractions (10 μg of protein per lane) were monitored by electrophoresis in 1.8 % agarose gel and visualized
with Coomassie Brilliant Blue staining.

Isolation of peritoneal macrophages and ex vivo
tissue cultures
Resident peritoneal macrophages were isolated from
asm − / − /ldlr − / − and asm + / + /ldlr − / − on either modified
or standard diets. Macrophages collected from three or four
animals were pooled together and plated in 35 mm dishes at
density ranging from 1.8×106 to 2.6×106 cells/dish. ABVs
(aorta and blood vessels) surrounding the heart were dissected,
cleared from visible debris of fat, cut longitudinally to expose
the endothelial cells and washed twice with PBS. ABVs from
mice in the same experimental group were cultured together in
a 35 mm dish. For ex vivo assays of the fat tissue, a piece of
epididymal fat from several animals (3–5 animals per group)
was dissected, washed twice with PBS and placed together
in 35 mm dish. Macrophages and ex vivo tissues were cultured in
DMEM (Dulbecco’s modified Eagle’s medium), supplemented
with 0.1 % FBS and 100 units/ml of penicillin/streptomycin mix
(Gibco Laboratories) for 5 h in a 37 ◦ C humidified incubator (5 %
CO2 ). Conditioned medium was collected, concentrated using
10 K Ultracell centrifugal filters (Amicon, Millipore) following
the manufacturer’s instructions and frozen for future use.

SMase activity assays
S-SMase and L-SMase (lysosomal SMase) activities were measured using C6 -NBD-SM as a substrate. Serum samples from mice
and concentrated conditioned medium were used as the source of
S-SMase. The standardized assay contained serum (2 μl) or medium (10 μl), 20 μM NBD-SM, 0.1 mM ZnCl2 , 0.1 M sodium
acetate buffer (pH 5.0) in a final volume of 20 μl. For L-SMase
activity, 10 μg of cell homogenates from macrophages were
used as the enzyme source. Reactions were allowed to continue for 3 h at 37 ◦ C and were stopped by the addition of 0.5 ml
of methanol. After further incubation at 37 ◦ C for 30 min, the
samples were centrifuged at 1000 g and the generation of fluorescent product, NBD-ceramide, was monitored by reverse-phase
HPLC using methanol/water/phosphoric acid (850:150:0.15, by
vol.) as a mobile phase [31].

Measurements of sphingolipid mass
Mass measurements of SM and Cer by TLC/HPLC
The lipids were extracted by the method of Blight and Dyer
[32] modified as described previously [33] and were analysed by TLC on silica gel 60 plates (10 cm×20 cm) using chloroform/methanol/triethylamine/2-propanol/0.25 % potassium chloride (30:9:18:25:6, by volume) as the developing
solvent. The regions migrating with a standard bovine brain
ceramide were scraped from the plate. To quantify the mass
of ceramide, the lipids were eluted from the silica with 1 ml of
chloroform/methanol (1:1, v/v) followed by 1 ml of methanol.

The combined elutes were dried in vacuo, then 0.5–1.0 mol of
internal standard, N-acetyl-C20 -sphinganine, was added to the
unknown ceramide sample and the ceramide mass was quantified by HPLC of the long-chain bases released after an acid
hydrolysis in 0.5 M HCl in methanol at 65 ◦ C for 15 h. Free longchain bases were analysed as described by Merrill et al. [34]. SM
mass was measured by two approaches with similar results. LDLs
were treated with bSMase (0.5 unit/ml) in 0.1 M Tris/HCl buffer,
pH 7.4 for 2 h at 37 ◦ C to promote hydrolysis of SM to ceramide.
The ceramide levels in SMase-treated and not-treated LDL were
measured as described above and the SM content was calculated
by subtracting ceramide mass measured in non-bSMase-treated
samples from those that were treated with bSMase. Hepatic SM
content was determined by TLC separation followed by measuring the Pi as described previously [13].

Lipid analysis using tandem MS
Total lipid extracts from 0.5 mg of liver tissue, 30 μl of serum
and 50 μg of VLDL and LDL were obtained using acidified organic solvents [35] with the addition of ceramide and SM internal
standards containing a C17:0 fatty acid (Avanti Polar Lipids). After
the lipid containing lower phase was evaporated to dryness under
N2 and reconstituted in methanol, molecular species of SM and
ceramide were detected by monitoring species-specific precursor
product ion pairs by HPLC–ESI (electrospray ionization) tandem
MS using 4000 Q-Trap hybrid linear ion trap triple-quadrupole
mass spectrometer as described previously [36] with minor modifications. Recovery was determined by reference to the internal
standards and quantification accomplished according to the calibration curves constructed using a set of synthetic standards for
each ceramide and SM species obtained from Avanti Polar Lipids
which were independently quantified by accurate mass measurements. SM containing cerotic (C26:0 ), lignoceric (C24:0 ), nervonic
(C24:1 ), behenic (C22:0 ), arachidic (C20:0 ), stearic (C18:0 ), oleic
(C18:0 ), palmitic (C16:0 ) and myristic (C14 ) acids was measured
and also ceramides with lignoceric acid (C24:0 ), nervonic (C24:1 ),
arachidic (C20:0 ), stearic (C18:0 ), oleic (C18:1 ), palmitic (C16:0 ) and
myristic (C14:0 ) acids.

TBARS (thiobarbituric acid-reactive substances)
and turbidity assays
Oxidation in LDL was determined spectrophotometrically by
measuring the amount of TBARS as described previously [37].
Briefly, 50 μg of LDL was precipitated with 0.25 ml of 20 %
trichloroacetic acid. Then, 0.625 ml 0.2 % thiobarbituric acid and
0.750 ml of 0.05 M sulfuric acid were added and the samples were
boiled for 30 min. After cooling down, addition of 1 ml of n-butyl
alcohol, vigorous vortex-mixing and phase separation at 1000 g
for 5 min, the absorbance was measured in the upper phase at
530 nm.
The susceptibility of LDL to aggregation was determined as
described previously with minor modifications [38]. LDL diluted
with PBS (0.25 mg/ml) was continuously vortex-mixed for up to
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Figure 1

S-SMase activity in serum
Mice of the indicated genotypes were placed on either a standard or modified diet for 10 weeks. S-SMase activity was
measured using C6 -NBD-SM as a substrate. (A) S-SMase activity in C57Bl6 mice measured by using 0.4 nmol of NBD-SM
per sample. Results are shown as means +
− S.D. (n = 3) for each mouse. (B–D) Michaelis–Menten kinetics of the S-SMase
activity in C57Bl6 and ldlr − / − mice on either standard or modified diet. The assays are carried out using serum (4–6
animals per assay) and the indicated substrate concentrations. Mean values of triplicates +
− S.D. are shown. *P < 0.05 and
**P < 0.01 according to a Student’s t test. SM/NBD-SM ratio in (D) was calculated by dividing the measured endogenous
LDL-SM concentration (presented in Table 1) and the amount of NBD-SM in each assay.

5 min and the changes in absorbance at 680 nm monitored at the
indicated times.

Statistical analyses
After assuming equal variances across groups, the observed differences were tested statistically using Student’s t test when two
groups with one variable were compared or two-way ANOVA
when the effects of the two parameters (diet and genotype) were
assessed. Results are means +
− S.D. and are representative of at
least two independent experiments. In the Figures, significance
of main diet and genotype effect is indicated by * and ∧ symbols,
while # indicates the significance of interaction effects.

RESULTS
Atherogenic diet increases S-SMase activity in
serum
The effect atherogenic (modified) diet has on serum S-SMase
activity and LDL sphingolipid content and properties was investigated using C57Bl6 and ldlr − / − mice. The latter are the
preferred animal model to study atherosclerosis and hypercholesterolaemia, because of their high serum LDL content and the
possibility to easily isolate particles for biochemical and biophysical analyses. At the same time, however, our previous studies
have shown that endogenous LDL distorts the S-SMase activity
assay due to substrate competition [39]. To avoid this, S-Smase

activity was also assayed in C57Bl6 mice that have negligible
endogenous LDL content.
Eight-week-old male mice (C57Bl6 and ldlr − / − ) were placed
for 10 weeks either on standard chow diet (18 % protein diet, containing 1 % saturated fats and no cholesterol) or a modified (atherogenic) one (42 % fat, calorie-adjusted diet, containing 13.8 %
saturated fats and 1.5 % cholesterol). S-SMase activity was measured in serum using NBD-SM as a substrate. Significant increases
in S-SMase activity were observed in C57Bl6 mice fed on the
atherogenic diet, as compared with C57Bl6 on standard chow
(Figure 1A). Judging by Michaelis–Menten analyses, both the
K m and V max of the enzyme reaction were affected (Figure 1B).
These results indicate that S-SMase activity is elevated in mice
fed on a modified diet.
In the ldlr − / − strain, however, diet-associated increases in
S-SMase activity were only evident when high concentrations
of the NBD-SM substrate were used (Figure 1C). Furthermore,
the substrate-dependence curves did not follow the classical
Michaelis–Menten pattern. One likely explanation is that the
serum from ldlr − / − mice on atherogenic diet has very high content of LDL (which carries the endogenous SM substrate of SSMase), which competes with the exogenous NBD-SM substrate
during the assay. Indeed, the calculated ratio between the endogenous SM present in each assay sample and the added NBD-SM
was above 1:100 for assays done with C67Bl6 mice on either diets
and remained in the 1:5–1:60 range for ldlr − / − mice fed on the
standard diet (Figure 1D). Owing to the diet-induced increases in
LDL-SM, however, this ratio decreased to between 1:1 and 1:12
in the ldlr − / − mice on modified diet and a competition between
the substrates became noticeable. Increasing the exogenous substrate to 60 nmol (when the ratio again became higher than 1:100)
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Table 1 Effects of atherogenic diet on lipoprotein and liver sphingolipid levels
ldlr − / − mice were placed on atherogenic diet for 10 weeks and sphingolipid classes were measured by TLC/HPLC. Serum from three or four animals
was pooled for the isolation of lipoprotein particles. Results are means +
− S.D. (n = 3). *P < 0.05. Cer, ceramide; DH-Cer, dihydroceramide.
Sphingolipid level (nmol/ml of serum)
Parameter

Sphingolipid

VLDL

SM
Cer
DH-Cer

LDL

SM
Cer
DH-Cer

HDL

SM
Cer
DH-Cer

LPDS

SM
Cer
DH-Cer

Liver

SM

Diet . . .

Standard

Modified

14.61 +
− 1.35
4.91 +
− 0.06
1.24 +
− 0.11
48.32 +
− 1.64
2.64 +
− 0.02
0.68 +
− 0.21
0.92 +
− 0.64
0.45 +
− 0.06
0.05 +
− 0.05
0.22 +
− 0.71
1.90 +
− 0.94
0.01 +
− 0.01
N/A

220.10 +
− 77.86*
16.27 +
− 2.18*
4.15 +
− 1.17*
227.64 +
− 15.07*
33.24 +
− 1.71*
5.43 +
− 1.82*
36.41 +
− 1.79*
3.48 +
− 1.54*
0.47 +
− 0.20*
2.09 +
− 0.20*
0.84 + 0.07
0.37 +
− 0.03*
N/A

Cer

N/A

N/A

DH-Cer

N/A

N/A

overcomes these shortcomings of the assay. Together, these results show conclusively that diet enriched in saturated fats and
cholesterol increases the activity of serum S-SMase in both animal models.

Atherogenic diet is associated with parallel
elevation of serum and hepatic sphingolipids
Analyses of sphingolipid content in total serum showed that, in
ldlr − / − mice on standard chow diet, SM at 64.07 nmol/ml is
the main serum sphingolipid. The concentrations of ceramide
and dihydroceramide were 9.9 and 1.98 nmol/ml respectively.
The diet caused drastic increases in the levels of serum SM to
486 nmol/ml, ceramide to 53.83 nmol/ml and dihydroceramide
to 10.42 nmol/ml respectively. The elevation in all serum sphingolipids in mice fed on the atherogenic diet was paralleled by
simultaneous accumulation of ceramide, dihydroceramide and
SM in the liver (Table 1), suggesting that the changes in serum
sphingolipid reflect increased sphingolipid synthesis in the liver
[13]. Indeed, previous studies had associated atherogenic diet
with stimulation of the de novo sphingolipid synthesis resulting
from increased flux of dietary palmitate into the sphingolipid
biosynthetic pathway and the induction of hepatic SPT mRNA
transcription and activity [13]. In turn, SPT stimulation has been
found to elevate hepatic secretion of SM and ceramide in vitro
[2]. The results in Table 1 are consistent with these previous findings and illustrate in vivo the paralleled effect of atherogenic diet
on hepatic and serum sphingolipids.
To delineate what role S-SMase has in regulating SM and
ceramide content of LDL particles, analyses of individual serum
lipoprotein classes were done. In mice on the atherogenic diet,
the levels of sphingolipids associated with all three lipoprotein

Sphingolipid level (nmol/mg of protein)
Diet . . .

Standard

Modified

52.19 +
− 4.85
17.21 +
− 0.22
4.37 +
− 0.38
59.65 +
− 2.02
3.22 +
− 0.02
0.84 +
− 0.32
2.29 +
− 1.62
1.11 +
− 0.14
0.14 +
− 0.01
0.05 +
− 0.01
0.12 +
− 0.06
0.04 +
− 0.07
0.50 +
− 0.02
0.64 +
− 0.04
+ 0.02
0.03 −

120.20 +
− 42.54*
8.89 +
− 1.19*
2.26 +
− 0.64*
115.88 +
− 25.03*
15.04 +
− 0.77*
2.81 +
− 0.82*
20.11 +
− 0.98*
1.92 +
− 0.85
0.26 +
− 0.11
0.06 +
− 0.01
0.03 +
− 0.01
0.60 +
− 0.01
1.90 +
− 0.40*
1.09 +
− 0.20*
+ 0.01*
0.09 −

types, VLDL, LDL and HDL, increased substantially (Table 1).
After data were normalized to the protein amount in each lipoprotein fraction, the concentration of SM in VLDL and LDL in
mice fed on the atherogenic diet remained significantly elevated,
indicating that these particles became enriched in SM. Ceramide
and dihydroceramide concentrations, on the other hand, increased
significantly only in LDL but not VLDL.

Diet-induced activation of S-SMase is accountable
for the ceramide enrichment of LDL
The role S-SMase plays in determining the ceramide enrichment of LDL was investigated in sera from asm − / − /ldlr − / −
and asm + / + /ldlr − / − mice placed on either modified or standard diet. In a previous study, we reported the generation of
this novel composite knockout mouse strain, in which asm
deficiency (asm − / − ) was introduced into ldlr − / − background
[13]. Feeding asm − / − /ldlr − / − mice and their respective controls, asm + / + /ldlr − / − , with atherogenic diet, revealed that the
lack of ASMase had no effect on diet-induced hypercholesterolaemia, and mice from both genotypes exhibited similar
increases in serum VLDL and LDL cholesterol and similar
lipoprotein profiles [13]. The experiments shown in Figure 2(A)
confirm that asm-deficient mice and wild-type control develop
comparable hypercholesterolaemia when placed on atherogenic
diet. The increases in LDL protein were also similar for both
genotypes (results not shown). As anticipated, the asm-null mice
have no detectable S-SMase activity thus confirming that SSMase is the only SM-hydrolysing enzyme in mouse serum
(Figure 2B). Mice deficient in S-SMase consequently have significantly higher LDL-SM content than their wild-type counterparts. This LDL-SM increases similarly for both genotypes
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Figure 2

Role of S-SMase in diet-induced changes in serum cholesterol levels and LDL-sphingolipid content
Mice of the indicated genotype were placed on either a standard or modified diet for 10 weeks (3–5 animals per group).
Total serum (A and B) or purified LDL particles (C–E) were analysed for total cholesterol (A), S-SMase activity (B), SM,
(C), ceramide (D) or the molar ratio of ceramide to SM (E). Values are means +
− S.D. (n = 3 animals per group). Statistical
significance was analysed using two-way ANOVA followed by Bonferonni post-hoc test. The results of the Bonferonni post-hoc
test with respect to the diet (*P < 0.05, **P < 0.01 and ***P < 0.001), genotype (∧∧ P < 0.01), as well as the interaction
effects from two-way ANOVA (# P < 0.05 and ## P < 0.01) are shown.

when placed on an atherogenic diet (Figure 2C). In contrast,
diet-induced increases in LDL-ceramide (and in the ceramide
to SM ratio) are substantially attenuated in the asm − / − /ldlr
−/−
mice (Figures 2D and 2E). The statistical significance of
the diet–genotype interaction effect based on two-way ANOVA
is P = 0.016 for LDL-ceramide (Figure 2D) and P = 0.01 for
the ceramide/SM ratio (Figure 2E) confirming that asm deletion
eliminates diet-induced accumulation of ceramide in the LDL
particles. This effect is specific for LDL since the corresponding elevation in ceramide observed in the liver is not reversed
by the ASMase deletion [13]. Collectively, these results provide
evidence that the activation of serum S-SMase facilitates the
conversion of LDL-SM into ceramide in mice on atherogenic
diet.

SM and ceramide levels affect the oxidation and
aggregation properties of LDL
To assess the physiological significance of the observed differences in SM and ceramide content, LDL particles from
asm + / + /ldlr − / − and asm − / − /ldlr − / − on either standard or
atherogenic diets were analysed for oxidation and aggregation
as described previously [22]. When run on agarose gel (Figure 3A), LDL from asm + / + /ldlr − / − and asm − / − /ldlr − / − mice
fed on the standard diet run as single bands. LDL particles from
asm + / + /ldlr − / − mice fed on the high-fat diet exhibited different
electrophoretic mobility, with some migrating very slowly (aggregated LDL) and others migrating at a higher rate and forming
a secondary band (oxidized LDL) (Figure 3A). These indications

for aggregation and oxidation were less pronounced in the LDL
from asm − / − /ldlr − / − mice. LDL oxidation and self-aggregation
were further assessed by measuring the levels of TBARS and by
assaying changes in turbidity. As shown in Figures 3(B) and
3(C), LDL particles from asm + / + /ldlr − / − mice on the modified diet exhibited higher TBARS values and marked increases
in the turbidity of the LDL solution, as compared with LDL from
asm + / + /ldlr − / − mice on a standard diet. In contrast, there was
little increase in the turbidity and, in fact, a decrease in TBARS
levels for LDL from asm − / − /ldlr − / − mice on a high-fat diet, as
compared with asm − / − /ldlr − / − mice on a standard diet. Such a
decrease is likely to reflect the higher SM content of the former.
As mentioned before, SM has been shown to protect against LDL
oxidation [25]. These results suggest that S-SMase activity contributes to the increased LDL oxidation and aggregation in mice
on an atherogenic diet.
To further confirm that the conversion of LDL-SM into ceramide is a key factor determining LDL aggregation and/or oxidation,
we incubated LDL particles from all groups with bSMase for 2 h
at 37 ◦ C to hydrolyse LDL-SM to ceramide. A control group
was treated with vehicle under the same conditions. The resulting increases in ceramide content correlated well with the initial
SM levels in each type of LDL particles (Figure 3D). bSMase
treatment had a pronounced effect on LDL electrophoretic mobility: (i) the proportion of particles that were retained at the
start of the gel (indication of aggregation) was elevated and (ii)
those particles that migrated into the gel had increased motility
(indication of oxidation) (Figure 3E). These effects confirm that
conversion of SM into ceramide increases LDL self-aggregation
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Figure 3

LDL biophysical properties and susceptibility to modifications
LDL particles were isolated by sequential ultracentrifugation from sera of asm − / − /ldlr − / − [labelled with ( − / − )] and
asm + / + /ldlr − / − [labelled with ( +/+ )] mice placed on either standard or modified diet for 10 weeks (3–5 animals
per group). (A) Electrophoretic mobility of LDL particles (10 μg of protein per lane) in 1.8 % agarose gel visualized by
Coomassie Brilliant Blue staining. (B) Oxidation of LDL assessed by measuring TBARS. Results are means +
− S.D. of
triplicate measurements. Statistical significance was analysed by two-way ANOVA followed by Bonferonni post-hoc test.
The results of the Bonferonni post-hoc test with respect to the diet (**P < 0.01), genotype (∧∧ P < 0.01) as well as the
genotype/diet interaction effect from two-way ANOVA (### P < 0.001) are shown. (C) Turbidity assay of LDL aggregation.
Changes in absorbance were monitored at 680 nm at the indicated times. (D) TLC/HPLC determination of the increase in
LDL ceramide content following treatment with bSMase (0.5 unit/ml). The increases in ceramide content due to bSMase
treatment were analysed for statistical significance using two-way ANOVA and Bonferonni post-hoc test with respect to diet
and genotype. The results of the Bonferonni test with respect to the diet (**P < 0.01 and ***P < 0.001) and genotype
(∧ P < 0.05 and ∧∧ P < 0.01) are shown. (E) Effect of bSMase treatment on the electrophoretic properties of LDL particles
(10 μg of protein) in 1.8 % agarose gel visualized by Coomassie Brilliant Blue staining. Representative results from at
least three independent experiments, including three different isolations of LDL, are shown. Std, Standard; Mod, modified.
(F) Quantification of the results shown in (E).

and/or oxidation. Notably, the rate of bSMase-induced selfaggregation correlates well with the initial levels of SM (Figure 3F). These results indicate that the LDL propensity for selfaggregation depends not only on the activity of S-SMase but also
on the amount of SM available for hydrolysis. For these reasons, LDL particles from asm + / + /ldlr − / − mice on standard diet
show the least susceptibility for aggregation, while those from
asm − / − /ldlr − / − fed on a high-fat diet and consequently having highest SM levels were most susceptible to SMase-induced
aggregation. Collectively, these findings suggest that, while SSMase activity is indeed involved in LDL aggregation, unless the
LDL particles have high levels of SM (such as those observed in
the mice fed on an atherogenic diet), the net impact of S-SMase
may be limited.

Atherogenic diet stimulates S-SMase secretion by
macrophages, but not by ABVs
Previous studies have suggested that ABVs and macrophages
are the main source of S-SMase activity [14,40]. Therefore, we
sought to determine whether these same cell types are responsible for the observed increase in S-SMase activity. Tissues were
collected from mice on the respective diets and cultured ex vivo
in the presence of defined growth media. After 5 h, the medium
was collected, concentrated and S-SMase activity was measured.
Only negligible activity was detected in the absence of Zn2 + ,
confirming that the activity measured was not due to enzymes
released from dying/lysed cells.
S-SMase activity under standard diet was high for ABVs, as
well as for resident peritoneal macrophages, while it was low for
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Figure 4 S-SMase and L-SMase activities in peritoneal macrophages, blood vessels and adipose tissue cultured ex vivo
Mice were placed either on standard or modified diets for 10 weeks
(3–5 animals per group). NBD-SM was used as a substrate to measure
Zn2 + -dependent S-SMase activity in conditioned medium or L-SMase
activity in cellular lysates. Results are normalized per mg of cellular
protein. Means +
− S.D. are shown. *P < 0.05 compared with mice of
same genotype on standard diet. (A) S-SMase activity in various tissues
+/+
of asm
/ldlr − / − mice. (B) S-SMase activity in resident peritoneal
macrophages from asm − / − /ldlr − / − and asm + / + /ldlr − / − mice.
(C) L-SMase activity in lysates prepared from the same macrophages.

epididymal adipose tissue (Figure 4A). The atherogenic diet had
seemingly no stimulatory effect on the S-SMase of ABVs and
fat tissue. If anything, the activity of ABVs tended to decline.
However, macrophages from mice on modified diet exhibited 2fold higher SMase activity. As expected, the S-SMase-deficient
mice had no detectable secretory activity associated with their
macrophages on either diet (Figure 4B). This confirmed that
the activity measured in our assays came solely from S-SMase.
Importantly, the observed diet-induced enzyme stimulation was
S-SMase-specific since the activity of the L-SMases, which is
produced by the same gene, was not induced (Figure 4C). The
ASMase activity in the cells actually declined, which could indicate re-direction of the intracellular trafficking of the ASMase
precursor away from the lysosomes and towards the secretory
pathways in macrophages of mice on the atherogenic diet. Such
a possibility is supported by published studies showing that atherogenic diet interferes with the mannose 6-phosphate receptor
system [41]. The latter is known to regulate the processing of the
lysosomal and secretory form of ASMase [3]. It is also possible,
however, that the decrease in macrophages ASMase results from
diet-induced accumulation of cholesterol, which is an ASMase
inhibitor [42]. Whatever the case, it is clear that high-fat diet has
an impact on macrophage S-SMase activity and/or secretion.

Effects of diet on liver and lipoprotein sphingolipid
fatty acid composition
The bioactive properties of sphingolipids seem to depend on the
length and saturation of the fatty acid attached to the primary

amine group in the sphingoid base [43–45]. Therefore RP-HPLC
(reverse-phase HPLC)–ESI–tandem MS analysis was used to determine whether an atherogenic diet affects the levels of sphingolipids with specific fatty-acid content (Figure 5). The major fatty
acids found in serum lipoprotein sphingolipids were nervonic
(C24:1 ), lignoceric (C24:0 ) and palmitic acid (C16:0 ). The liver
sphingolipids exhibited similar fatty-acid distribution, confirming previous studies [46]. The levels of all measured ceramide
and SM species were elevated in mice fed on the modified diet.
Importantly, the increases in C16:0 -containing sphingolipids, however, were larger than those for sphingolipids with unsaturated or
very-long-chain saturated fatty acids. As a result, the occurrence
of sphingolipids with C16:0 fatty acid in liver and lipoproteins
of mice on an atherogenic diet increased, reflecting the high
abundance of palmitate in the diet. It should be noted that elevated C16:0 sphingolipid content has been associated with increased rate of apoptosis and fibrosis in liver [46,47]. Thus, the observed increases in the fraction of sphingolipids with C16:0 fatty
acid on palmitate-enriched diet could be associated with some of
the pathology characteristics of cardiovascular diseases.

Serum ceramide and SM profiles of
ASMase-deficient mice
Lastly, we addressed the question whether S-SMase has any preference towards SM with a specific fatty acid length and/or saturation (Figure 6). The major ceramide species found in the
serum of asm − / − /ldlr − / − and asm + / + /ldlr − / − mice on both
diets were C24:1 ceramide, followed by C24:0 and C16:0 ceramides
(Figure 6A), which is similar to what is seen in the serum of
healthy humans [23]. The most prominent SM species were C24:0
and C16:0 (Figure 6B). The ceramide/SM ratios for all species
were uniformly affected by the diet for both mouse genotypes.
This indicates that S-SMase has no apparent specificity for a
substrate with a particular fatty acid. Some preference, however,
may exist for the very long fatty-acid chains, since the genotyperelated changes in C24:0 species appeared to be somewhat larger
than those for the C16:0 species.

DISCUSSION
In the present study, we describe how a diet rich in saturated
fats and cholesterol affects the regulation of serum S-SMase
activity and, consequently, LDL aggregation in mice. The results presented here indicate that S-SMase activity and the pool of
its substrate in the form of LDL-SM are increased simultaneously
and that these are two key factors that influence LDL aggregation. We also show that S-SMase activity is required for LDL
aggregation; however, unless the LDL particles have sufficiently
high SM levels (such as those observed during consumption of
an atherogenic diet), the net impact of S-SMase may be limited.
SM is the second most abundant phospholipid class in LDL
particles and together with phosphatidylcholine makes up the
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Figure 5

Fatty acid composition of the SM and ceramide in liver, VLDL and LDL
Acidified organic solvents were used to prepare total lipid extracts from liver homogenates, VLDL and LDL from
asm + / + /ldlr − / − mice (three to five animals per group) fed either standard or modified diet. Ceramide and SM internal standards containing a C17:0 fatty acid were added at the start to account for any losses during the extraction.
Sphingolipid species containing different fatty acids were detected by monitoring species-specific precursor product ion
pairs using HPLC–ESI–tandem MS and 4000 Q-Trap hybrid linear ion trap triple-quadrupole mass spectrometer. Levels of
the respective dihydro species were sometimes too low for proper quantification and therefore were not included.

surface of the lipoproteins [48]. The main determinant of serum
SM levels is the rate of its synthesis and secretion by the liver
in the form of VLDL. This VLDL is later modified to LDL via
the action of various lipases [49]. In the liver, the synthesis of
SM is controlled by the rate of the SPT reaction, which is a ratelimiting step of sphingolipid biosynthesis [1]. Palmitic acid, the
most abundant fatty acid in many pro-atherogenic diets is also
the sole fatty acid used as a substrate of SPT. Numerous studies
have reported that an increased supply of palmitate stimulates
SPT activity and leads to the accumulation of dihydroceramide,
ceramide, SM and other complex sphingolipids in liver, muscle
and fat tissue [50]. The experiments described in the present study
provide the first evidence that diet-induced changes in sphingolipid content are not limited to these tissues but are passed on to the
serum lipoproteins. Elevation of serum VLDL and LDL cholesterol is the hallmark of atherosclerosis and is a well-established
consequence of extended consumption of diets that are rich in
saturated fats and cholesterol. Our studies provide evidence that
the elevated serum cholesterol is paralleled by elevation in serum
sphingolipids. In magnitude, the changes in SM synthesis seemingly surpass the stimulation of VLDL and LDL secretion, causing the production of particles that are enriched in SM.
The experiments shown in this study also reveal that LDL-SM
influences the propensity of LDL for aggregation. The underly-

ing mechanism apparently involves two independent steps. First,
diet-induced stimulation of de novo SM synthesis in the liver
results in the secretion of LDL particles that are enriched in SM,
providing excess substrate for S-SMase. Secondly, simultaneous
stimulation of S-SMase activity causes the increased conversion
of LDL-SM into ceramide, leading to aggregation. Previous studies from Ira Tabas’s group, which first characterized S-SMase
activity, have shown that recombinant bacterial SMase can hydrolyse SM in human LDL, inducing aggregation [51]. Our work
builds upon these findings to further show that LDL isolated
from animals deficient in S-SMase that are fed on an atherogenic
diet are in fact less aggregated and oxidized than LDL from animals with a functional S-SMase. These observations are direct
indications for the key role S-SMase plays in LDL aggregation
and are also consistent with the previously reported decrease in
diet-induced plaque formation in asm − / − /ldlr − / − mice [28].
The LDL susceptibility for aggregation depends on the levels
of S-SMase substrated LDL-SM. In the present study, LDL from
asm − / − /ldlr − / − animals fed on an atherogenic diet that had
the highest SM content, were most susceptible to aggregation
upon treatment with bSMase. In contrast, particles from
asm + / + /ldlr − / − mice on the standard diet had the lowest SM
content and aggregated the least when similarly treated. These
observations suggest that LDL-SM in animals on a standard diet
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Figure 6

Ceramide and SM species in the serum of mice on atherogenic or control diet
Total serum lipid extracts were prepared from asm − / − /ldlr − / − and asm + / + /ldlr − / − mice placed on either standard
(Std) or modified (Md) diet for 10 weeks. Ceramide (A) and SM (B) species were quantified by monitoring precursor product
ion pairs using HPLC–ESI/tandem MS. The ceramide/SM molar ratio was calculated in each sample (C). Means +
− S.D.
are shown (n = 3 animals per group). Bonferonni post-hoc test analyses comparing the effect of the diet for mice from the
#
same genotype are shown (*P < 0.05 and P < 0.001). Std, standard diet; Md, modified diet.

is so low that even its complete conversion into ceramide is not
sufficient to induce aggregation without diet-induced SM enrichment of LDL particles. In support of this notion, it has been reported that LDL particles isolated from SM synthase 2 transgenic
mice aggregate more when treated with recombinant SMase than
LDL from wild-type mice [52].
Another important finding of our studies is that palmitate-rich
diet not only elevates SM and ceramide content but also modifies the fatty acid profile of these sphingolipids by increasing
the proportion of C16:0 species. The bioactive properties of ceramide are known to depend on the length and saturation of the
fatty acid attached to the primary amine group in the sphingoid base [43–45]. An elevated proportion of C16 -sphingolipids
in the liver is associated with increased apoptosis, even in the
absence of net accumulation of ceramide [46,47]. In our study,
the atherogenic diet led to the hepatic accumulation of sphingolipid species that are potentially detrimental to cellular functions
and could be involved in some of the pathologies and complications typical of atherosclerosis. Whether or not the specific increases in LDL C16:0 ceramide and SM affect LDL properties is
not clear. However, uptake of LDL with elevated ceramide content by vascular endothelial cells has been linked to increased

apoptosis [22]; therefore the enrichment with C16:0 and C18:0 species may have indirect effects in such cases of LDL particle
uptake.
In conclusion, S-SMase is emerging as a key regulator of
LDL aggregation, based on direct evidence from knockout animal
models of atherosclerosis presented in this work as well as in
previous reports by other investigators. Importantly, the effects
of S-SMase are dependent on the SM content of LDL, which is
substantially increased by the atherogenic diet. Furthermore, the
fatty-acid composition of sphingolipids is seemingly sensitive to
changes in dietary fat that might be vital for understanding the
effects saturated fatty acids have on cell functions.
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